Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 9Cyclophosphamide 9ibrutinib 7fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4fludarabine 3Vincristine 3Prednisone 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Etoposide 3Doxorubicin 3Carmustine 3Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Cyclosporine 2Cord Blood Stem Cell Transplantation 2CT-P10 2Bortezomib 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Mantle-Cell × Spinal Puncture × Clear all
NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡